In Japan, the rheumatic arthritis drug “Baricitinib”, produced by a US pharmaceutical company, has been approved for use in the treatment of coronavirus.
Japan’s Ministry of Health, Labor and Welfare’s expert panel approved the use of the rheumatic arthritis drug “Baricitinib” pills in the treatment of a new type of coronavirus (Covid-19).
The pills “Baricitinib”, a rheumatic arthritis drug produced by Eli Lily of the United States, were approved by the expert health committee within the ministry, Kyodo reported.
The company applied to the ministry for approval of the drug in December. The ministry is expected to formally approve the use of the drug within a month.
“Baricitinib” was approved in the U.S. to be used in addition to the anti-viral drug “Remdesivir” in the treatment of Covid-19 patients who need oxygen supplements.
The Japanese government has so far approved the drugs “Remdesivir” and “steroid dexamethasone” in the treatment of Covid-19.